Hypermethylation of the MGMT promoter is considered a predictive biomarker for the response to temozolomide (TMZ), an alkylating agent playing a crucial role in the treatment of glioblastoma multiforme (GBM) [30]. Here, MGMT is linked to glioblastoma.